S. Toma et al., Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients, INT J ONCOL, 17(5), 2000, pp. 991-1000
In addition to suppressing breast cancer cell growth, retinoids potentiate
growth inhibition in human breast cancer when tested in vitro and in vivo w
ith tamoxifen and/or interferon. The purpose of this study was to ascertain
the biologic effects of all-trans-retinoic acid (ATRA) administered alone
and with tamoxifen +/- interferon and to identify the relationship between
ATRA plasma concentrations and optimal biological dose (the lowest dose tha
t produces a biological response). Three consecutive groups of 15 patients
with locally advanced operable breast cancer were treated, in accordance wi
th good clinical practice (GCP) requirements, with ATRA at 3 dose levels al
one or with tamoxifen +/- alpha-interferon 2a at flat doses. After 3 weeks,
the tumors were surgically removed. Biological parameters measured at the
beginning (in biopsy tissue) and end (in surgical tissue) of the study were
compared. The optimal biological dose for ATRA was 15 mg/m(2)/day. Treatme
nts influenced tumor grade but not cell cycle kinetics (G(0)-G(1) phase) or
proliferation (Ki67 levels). ATRA induced progesterone receptors independe
nt of dose level and co-administered drugs, but did not induce estrogen rec
eptors when administered alone. Retinoic acid receptor (RAR)-alpha was not
affected by treatment and RAR-alpha was moderately influenced whereas RAR-b
eta (concomitantly with transforming growth factor-beta) was induced in 33%
of patients by ATRA alone. ATRA pharmacokinetics were dose- and time-depen
dent. Neither the ATRA + tamoxifen nor the ATRA + tamoxifen + interferon co
mbinations potentiated the ATRA-induced biological changes. Future studies
evaluating the role of RAR-beta as a biological marker of retinoid activity
are warranted.